Teligent (TLGTQ) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 04, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	Teligent, Inc.
Entity Central Index Key	352,998
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	TLGT
Entity Common Stock, Shares Outstanding		53,059,273

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Product sales, net	$ 15,422	$ 10,510
Research and development services and other income	235	161
Total revenues	15,657	10,671
Costs and Expenses:
Cost of revenues	7,702	5,043
Selling, general and administrative expenses	3,407	1,900
Product development and research expenses	3,711	2,630
Total costs and expenses	14,820	9,573
Operating income	837	1,098
Other Income (Expense):
Change in the fair value of derivative liability	0	8,625
Foreign currency exchange gain	1,553	0
Interest and other expense, net	(3,318)	(3,168)
(Loss) income before income tax expense	(928)	6,555
Income tax expense	22	0
Net (loss) income	$ (950)	$ 6,555
Basic earnings (loss) per share	$ (0.02)	$ 0.12
Diluted earnings (loss) per share	$ (0.02)	$ 0.01
Weighted average shares of common stock outstanding:
Basic (in shares)	53,031,351	52,841,900
Diluted (in shares)	53,031,351	67,210,177

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 87,040	$ 87,191
Accounts receivable, net	13,159	14,028
Inventories	10,091	8,985
Prepaid expenses and other receivables	7,450	6,597
Total current assets	117,740	116,801
Property, plant and equipment, net	11,125	8,706
Debt issuance costs, net	3,830	4,027
Intangible assets, net	54,916	54,320
Goodwill	459	426
Other	474	482
Total assets	188,544	184,762
Current liabilities:
Accounts payable	4,437	3,955
Accrued expenses	8,163	6,267
Deferred income, current	324	476
Capital lease obligation, current	40	70
Total current liabilities	12,964	10,768
Convertible 3.75% senior notes, net of debt discount (face of $143,750)	108,800	106,991
Deferred tax liability	261	244
Total liabilities	122,025	118,003
Stockholders’ equity:
Common stock, $0.01 par value, 60,000,000 shares authorized; 53,059,273 and 53,000,689 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	550	549
Additional paid-in capital	100,011	99,258
Accumulated deficit	(33,868)	(32,918)
Accumulated other comprehensive loss, net of taxes	(174)	(130)
Total stockholders' equity	66,519	66,759
Total liabilities and stockholders' equity	$ 188,544	$ 184,762

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	53,059,273	53,000,689
Common stock, shares outstanding	53,059,273	53,000,689
Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.75%	3.75%
Debt Instrument, Face Amount	$ 143,750	$ 143,750

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net (loss) income	$ (950)	$ 6,555
Other Comprehensive (loss) income, net of tax
Foreign currency translation adjustment	(44)	0
Other Comprehensive loss	(44)	0
Comprehensive (loss) income	$ (994)	$ 6,555

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Including Portion Attributable to Noncontrolling Interest [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 66,759	$ 549	$ 99,258	$ (130)	$ (32,918)
Balance (in Shares) at Dec. 31, 2015		53,000,689
Stock based compensation expense	753		753
Stock options exercised	1		1
Stock options exercised (in Shares)		1,000
Issuance of stock for vested restricted stock units	0	$ 1	(1)
Issuance of stock for vested restricted stock units (in Shares)		52,584
Issuance of stock to a consultant	36		36
Issuance of stock to a consultant (in Shares)		5,000
Costs related to recovery from stockholder	(36)		(36)
Cumulative translation adjustment	(44)			(44)
Net loss	(950)	$ 0	0	0	(950)
Balance at Mar. 31, 2016	$ 66,519	$ 550	$ 100,011	$ (174)	$ (33,868)
Balance (in Shares) at Mar. 31, 2016		53,059,273

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (950)	$ 6,555
Reconciliation of net (loss) income to net cash provided by (used in) operating activities
Depreciation and amortization of fixed assets	174	118
Amortization of license fee	0	25
Stock based compensation	753	378
Amortization of debt issuance costs	197	195
Amortization of Intangibles	705	30
Foreign currency exchange gain	(1,553)	0
Amortization of debt discount on convertible 3.75% senior notes	1,809	1,590
Change in the fair value of derivative liability	0	(8,625)
Changes in operating assets and liabilities
Accounts receivable	927	(1,939)
Inventories, net	(954)	(938)
Prepaid expenses and other current receivables	(545)	(148)
Other assets	8	0
Accounts payable and accrued expenses	2,364	2,705
Deferred income	(153)	(60)
Net cash provided by (used in) operating activities	2,782	(114)
Cash flows from investing activities:
Product acquisition costs	(330)	(1,500)
Capital expenditures	(2,586)	(211)
Net cash used in investing activities	(2,916)	(1,711)
Cash flows from financing activities:
Proceeds from exercise of common stock options and warrants	1	15
Principal payments on capital lease obligations	(30)	(33)
Debt issuance costs	0	(9)
Costs related to recovery from stockholder	(36)	0
Net cash used in financing activities	(65)	(27)
Effect of exchange rate on cash and cash equivalents	48	0
Net decrease in cash and cash equivalents	(199)	(1,852)
Cash and cash equivalents at beginning of period	87,191	158,883
Cash and cash equivalents at end of period	87,040	157,031
Supplemental Cash flow information:
Cash payments for interest	1	49
Cash payments for income taxes	22	45
Non cash investing and financing transactions:
Issuance of stock to a consultant	36	0
Restricted Stock [Member]
Non cash investing and financing transactions:
Issuance of restricted stock	$ 0	$ 347

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	Mar. 31, 2016	Mar. 31, 2015
Senior Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.75%	3.75%

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	Organization and Business Teligent, Inc., and its subsidiaries, (collectively the “Company”), is a specialty generic pharmaceutical company. Our mission is to become a leader in the specialty generic pharmaceutical market. Under our own label, we currently market and sell generic topical and branded and generic injectable pharmaceutical products in the United States and Canada. In the United States we currently market nine generic topical pharmaceutical products and four branded generic injectable pharmaceutical products. Through the completion of an acquisition, we now sell a total of eighteen generic and branded generic injectable products and medical devices in Canada. Generic pharmaceutical products are bioequivalent to their brand name counterparts. We also provide development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (“OTC”), and cosmetic markets. We operate our business under one segment. Effective October 23, 2015, we changed our name from IGI Laboratories, Inc. to Teligent, Inc. On October 26, 2015, our common stock, which was previously listed on the NYSE MKT, began trading on the NASDAQ Global Select Market under the trading symbol “TLGT.” Our office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Liquidity The Company’s principal sources of liquidity are cash and cash equivalents of approximately $ 87 Company terminated its 10 with General Electric Capital Corporation, as agent, and GE Capital Bank and certain other institutions, as lenders, On December 10, 2014, the Company entered into a purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell its 3.75 139 4.8 The sale was completed on December 16, 2014. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity or through a strategic alliance with a third party. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that its existing capital resources will be sufficient to support its current business plan and operations beyond May 2017.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the vesting period of the grant. The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, notes payable, accounts payable, capital leases and other accrued liabilities at March 31, 2016 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, "Fair Value Measurements and Disclosures". ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company measures its derivative liability at fair value. The derivative embedded convertible option related to the Notes issued December 16, 2014 was valued using the “with” and “without” analysis. A “with” and “without” analysis is a standard valuation technique for valuing embedded derivatives by first considering the value of the Notes with the option and then considering the value of the Notes without the option. The difference is the fair value of the embedded derivatives. The embedded derivative is classified within Level 3 because it is valued using the “with” and “without” method, which does utilize inputs that are unobservable in the market. On May 20, 2015, the Company received approval to increase its authorized shares sufficient to allow for the conversion of the entire note into equity at its annual shareholders meeting. Therefore, the derivative liability of $ 18.3 23.1 108.8 143.75 Basic earnings (loss) per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the Notes and the exercise of options and warrants. For the three months ended March 31, 2016 and 2015 (in thousands except shares and per share data) 2016 2015 Basic earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Weighted average common shares - basic 53,031,351 52,841,900 Basic (loss) earnings per share $ (0.02) $ 0.12 Dillutive earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Interest expense related to convertible 3.75% senior notes - $ 1,348 Amortization of discount related to convertible 3.75% senior notes - $ 1,590 Change in the fair value of derivative - (8,625) Net (loss) income - diluted $ (950) $ 868 Share Computation: Weighted average common shares - basic 53,031,351 52,841,900 Effect of convertible 3.75% senior notes - 12,732,168 Effect of dilutive stock options and warrants - 1,636,109 Weighted average common shares outstanding - dilluted 53,031,351 67,210,177 Dilluted (loss) earnings per share $ (0.02) $ 0.01 The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, “Revenue Recognition The Company derives its revenues from three basic types of transactions: sales of its own pharmaceutical products, sales of manufactured product for its customers included in product sales, and research and product development services and other services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Three months ended March 31, 2016 2015 Company product sales $ 9,191 $ 8,096 Contract manufacturing sales 6,231 2,414 Product sales, net $ 15,422 $ 10,510 Company Product Sales : The Company records revenue from Company product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales from Company label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of SRA is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the SRA reserves. The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90 95 Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses. (in thousands) Three months ended March 31, 2016 2015 Gross Company product sales $ 26,823 $ 22,307 Reduction to gross product sales: Chargebacks and billbacks 12,345 12,512 Sales discounts and other allowances 5,287 1,699 Total reduction to gross product sales 17,632 14,211 Company product sales, net $ 9,191 $ 8,096 Net Company product sales of $ 9.2 8.1 15.6 6.1 2.1 2.9 40 0.5 0.9 0.5 0.9 10,000 0 10,000 0 Contract Manufacturing Sales : The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products and are included in product sales, net on the Company’s Condensed Consolidated Statement of Operations. Research and Development Services and Other Income : The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed. Other types of revenue include royalty or licensing revenue, and would be recognized based upon the contractual agreement upon completion of the earnings process. Major customers of the Company are defined as having revenue greater than 10 64 69 57 . Expansion into foreign operations in the fourth quarter of 2015 has generated net revenues greater than 10 13.4 2.2 136.4 52.1 The Company accounts for its derivative instruments in accordance with ASC 815-10, “Derivatives and Hedging”. ASC 815-10 establishes accounting and reporting standards requiring that derivative instruments, including derivative instruments embedded in other contracts, be recorded on the balance sheet as either an asset or liability measured at its fair value. ASC 815-10 also requires that changes in the fair value of derivative instruments be recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. The Company's derivative liability was the embedded convertible option of its Notes issued December 16, 2014 (see Note 6), which has been recorded as a liability at fair value until May 20, 2015, and was revalued at each reporting date, with changes in the fair value of the instruments included in the consolidated statements of operations as non-operating income (expense). Due to the approval of the sufficient shares at the Company’s annual shareholder meeting, the liability for the embedded derivative was reclassified to equity on May 20, 2015. The Company has no derivatives at March 31, 2016 and December 31, 2015. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In March 2016, the FASB ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): “Improvements to Employee Share-Based Payment Accounting”. The update includes multiple provisions intended to simplify various aspects of the accounting for share-based payments, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any interim or annual period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventories Inventories at March 31, 2016 and December 31, 2015 consist of the following: March 31, 2016 December 31, 2015 (Unaudited) (Audited) ( in thousands) Raw materials $ 4,854 $ 4,833 Work in progress 98 128 Finished goods 5,139 4,024 Total $ 10,091 $ 8,985

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment March 31, 2016 December 31, 2015 (Unaudited) (Audited) (in thousands) Land $ 257 $ 257 Building and improvements 5,426 5,296 Machinery and equipment 6,967 5,270 Construction in progress 4,360 3,594 17,010 14,417 Less accumulated depreciation and amortization (5,885) (5,711) Property, plant and equipment, net $ 11,125 $ 8,706 The Company recorded depreciation and amortization expense of $ 174,000 118,000 22,000 0

Convertible 3.75% Senior Notes

Convertible 3.75% Senior Notes	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible debt disclosure [Text Block]	Convertible 3.75% Senior Notes On December 16, 2014, the Company issued $ 125 3.75 18.75 139 4.8 1.6 The Notes bear interest at a fixed rate of 3.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2015, and mature on December 15, 2019, unless earlier repurchased, redeemed or converted. The Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. On May 20, 2015, the Company received shareholder approval for the increase in the number of shares of common stock authorized and available for issuance upon conversion of the Notes. As a result, the conversion option can now be share-settled in full, and now qualifies for equity classification, and the bifurcated derivative liability no longer needs to be accounted for as a separate derivative on a prospective basis as of May 20, 2015. The remaining unamortized debt discount that arose at the date of debt issuance from the original bifurcation will continue to be amortized using the effective interest method through interest expense. After adjusting the derivative liability to market value on May 20, 2015, the Company reclassified the entire $ 18.3 The Notes and any common stock issuable upon conversion of the Notes have not been registered under the Securities Act, applicable state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The Company does not intend to file a registration statement for the resale of the Notes or any common stock issuable upon conversion of the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. Since the Company did not have sufficient authorized shares available to share-settle the conversion option in full prior to May 20, 2015, the embedded conversion option did not qualify for equity classification and instead was separately valued and accounted for as a derivative liability. On December 16, 2014, the initial value allocated to the derivative liability was $ 43.7 143.75 12.94 8.6 23.1 The remaining unamortized discount and unamortized debt financing costs will be amortized over the remaining term of the debt of 3.75 March 31, December 31, 2016 2015 (in thousands) Face amount of the Notes $ 143,750 $ 143,750 Unamortized discount 34,950 36,759 Carrying amount of the Notes $ 108,800 $ 106,991 Deferred financing costs associated with the Notes include fees of $ 3.8 4.6 Initial Measurement Measurement Measurement December 16, December 31, May 20, 2014 2014 2015 Issue date 12/17/2014 12/17/2014 12/17/2014 Maturity date 12/15/2019 12/15/2019 12/15/2019 Term 4.99 4.92 4.57 Principal (millions) 143.75 143.75 143.75 Coupon 3.75 % 3.75 % 3.75 % Seniority Senior unsecured Senior unsecured Senior unsecured Conversion shares 88.572 88.572 88.572 Conversion price $ 11.29 $ 11.29 $ 11.29 Stock price $ 9.45 $ 8.80 $ 5.73 Risk free rate 1.61 % 1.64 % 1.44 % Volatility (rounded) 40.00 % 40.00 % 46.00 % Three months ended March 31, 2016 March 31, 2015 (in thousands) Interest Expense at 3.75% coupon rate $ 1,347 $ 1,348 Debt discount amortization 1,809 1,590 Amortization of deferred financing costs 197 173 Total interest expense (1) $ 3,353 $ 3,111 (1) Included within "Interest and other expense, net" on the Consolidated Statements of Operations

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	7. Goodwill and Intangible Assets Goodwill The Company acquired the assets of Canadian pharmaceutical company Alveda Pharmaceuticals, Inc., in November 2015. As a result of the acquisition, we recorded goodwill of $ 0.4 Goodwill December 31, 2015 $ 426 Acquisition - Impairments - Foreign currency translation 33 March 31, 2016 $ 459 Intangible Assets March 31, 2016 Weighted Average Gross Carrying Accumulated Net Carrying Remaining Amortization Amount Amortization Amount Period Trademarks and Technology $ 48,611 $ (1,269) $ 47,343 14.62 In process research and development ("IPR&D") 4,015 - 4,015 N/A - Indefinite lived Customer relationships 3,688 (131) 3,557 9.63 Total $ 56,315 $ (1,399) $ 54,916 December 31, 2015 Weighted Average Gross Carrying Accumulated Net Carrying Remaining Amortization Amount Amortization Amount Period Trademarks and Technology $ 47,679 $ (651) $ 47,028 14.8 In process research and development ("IPR&D") 3,875 - 3,875 N/A - Indefinite lived Customer relationships 3,460 (43) 3,417 9.9 Total $ 55,014 $ (694) $ 54,320 We test for impairment of definite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified during the three months ended March 31, 2016 and March 31, 2015, and therefore no impairment loss was recognized in the three months ended March 31, 2016 and March 31, 2015. Trademarks and Customer Technology IPR&D Relationships December 31, 2015 $ 47,028 $ 3,875 3,417 Acquisition 330 - - Amortization (618) - (87) Foreign currency translation 603 140 227 March 31, 2016 47,343 4,015 3,557 Amortization Expense * 2016 (remainder of the year) $ 2,203 2017 2,937 2018 2,937 2019 2,937 2020 2,937 2021 2,937 *IPR&D amounts will be amortized once products become saleable, and are not included in the table above.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. Stock-Based Compensation Stock Options The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 2,634,798 807,782 The 1999 Stock Incentive Plan, as amended (“1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those previous plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 2,892,500 100 On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by partial written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan became effective on July 29, 2009. The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units (“RSUs”) and performance awards. The 2009 Plan was created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 5,000,000 1,000,000 3,395,869 188,234 1,506,248 230,420 In summary, there are 4,045,869 T here are 122,201 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. The interest rates used are the U.S. Treasury yield curve in effect at the time of the grant. For the three months ended March 31, 2016 March 31, 2015 Expected volatility 68.0% - 69.9 % 52.7% - 55.2 % Expected term (in years) 3.2 -3.3 years 3.2 -3.3 years Risk-free rate 1.15 % 0.89% - 1.14 % Expected dividends 0 % 0 % A summary of option activity under the 1999 Plan, the Director Plan and the 2009 Plan as of March 31, 2016 and changes during the period are presented below: Weighted Number of Average Options Exercise Price Outstanding as of January 1, 2016 3,592,734 $ 4.36 Issued 485,135 $ 7.46 Exercised (1,000) $ 1.10 Forfeited (31,000) $ 8.64 Expired - - Outstanding as of March 31, 2016 4,045,869 $ 4.70 Exercisable as of March 31, 2016 2,533,202 $ 2.57 Based upon application of the Black-Scholes option-pricing formula described above, the weighted-average grant-date fair value of options granted during the three months ended March 31, 2016 and March 31, 2015, were $ 3.53 3.84 Outstanding: Weighted Stock Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.79 - $1.00 50,000 $ 0.79 3.76 $1.01 - $1.50 1,861,400 $ 1.07 5.89 $1.51 - $10.67 2,134,469 $ 7.95 8.97 Total 4,045,869 $ 4.70 7.49 Exercisable: Stock Weighted Options Average Range of Exercise Prices Exercisable Exercise Price $0.79 - $1.00 50,000 $ 0.79 $1.01 - $1.50 1,851,400 $ 1.07 $1.51 - $10.67 631,802 $ 7.12 Total 2,533,202 $ 2.57 As of March 31, 2016, the intrinsic value of the options outstanding was $ 7.9 7.8 3,800 4.8 Restricted Stock and RSUs The Company periodically grants restricted stock and RSU awards to certain officers and other employees that typically vest one to three years from their grant date. The Company recognized $ 180,000 99,300 1.6 Number of Weighted Average RSUs Exercise Price Non-vested balance at January 1, 2016 182,750 $ 10.23 Changes during the period: Shares granted 58,068 7.50 Shares vested (52,584) 10.67 Shares forfeited - - Non-vested balance at March 31, 2016 188,234 $ 9.26

Stock Warrants

Stock Warrants	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Stock Warrants 2015 Weighted Number of Average Warrants Exercise Price Balance at January 1, 84,000 $ 1.21 Changes during the period: Stock warrants granted - - Stock warrants expired - - Stock warrants exercised - 1.21 Balance at March 31, 84,000 $ 1.21 In connection with the private placement of the Company’s common stock on December 8, 2010, the Company granted common stock warrants to purchase up to 338,182 16,364 1.21

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	10. Income Taxes As a result of a recent acquisition, the Company now conducts operations and is subject to tax in certain foreign countries. It is the intent of the Company to permanently reinvest any earnings and profits generated by its foreign affiliates. Additionally, one of its foreign affiliates is subject to tax in Estonia. Estonia has a dual tax rate: 0 20 20 At December 31, 2015, the Company’s U.S. federal net operating loss carryforwards totaled $ 35.6 50 5 7.8 1.0 2.3 The Company is subject to the provisions of ASC 740-10-25, “ Income Taxes”

Legal

Legal	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies [Text Block]	11. Legal The Company is involved from time to time in claims which arise in the ordinary course of business. In the opinion of management, the Company has made adequate provision for potential liabilities, if any, arising from any such matters. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings (whether civil or criminal), settlements, judgments and investigations, claims and changes in any such matters, and developments or assertions by or against the Company relating to intellectual property rights and intellectual property licenses, could have a material adverse effect on its business, financial condition and operating results. On May 21, 2015, Horizon Pharma Ireland Limited, HZNP Limited and Horizon Pharma USA, Inc., (collectively “Horizon”), On June 30, 2015, August 11, 2015, September 17, 2015, October 27, 2015 and February 5, 2016, Horizon filed additional complaints in the United States District Court for the District of New Jersey against the Company alleging infringement of other of its United States patents in relation to the Company’s submission of the same ANDA. On July 21, 2015, September 11, 2015, October 6, 2015, October 21, 2015, December 17, 2015, and March 17, 2016 the Company filed answers, affirmative defenses and counterclaims with respect to the complaints filed by Horizon. In those filings, the Company asserted that the patents alleged to be infringed in the complaints filed by Horizon are invalid and not infringed by us. On April 27, 2016, Horizon and Teligent filed a stipulation of dismissal to dismiss the cases. The court entered an order dismissing the cases on May 2, 2016. On May 9, 2016, Horizon and Teligent entered into a settlement agreement. Under the settlement agreement, Teligent obtained a license to market diclofenac topical solution 2% no later than January 10, 2029 or earlier in certain circumstances, including the resolution by settlement or court decision of other third party litigation involving diclofenac topical solution 2% or the market entry by other third party generic versions of diclofenac topical solution 2%. At this time, Teligent cannot estimate if or when any of those earlier events might occur. On December 4, 2015, Galderma Laboratories, L.P. and Galderma S.A., collectively referred to as Galderma, filed a complaint in the United States District Court for the Northern District of Texas against the Company alleging infringement of United States Patent No. 6,106,848 based upon the Company’s submission to the FDA of an ANDA seeking FDA approval to market clobetasol propionate lotion 0.05% before the expiration patent asserted in the complaint.

Asset Purchase Agreements

Asset Purchase Agreements	3 Months Ended
	Mar. 31, 2016
Asset Purchase Agreement Disclosure [Abstract]
Asset Purchase Agreement Disclosure [Text Block]	12. Asset Purchase Agreements Sebela On March 31, 2016, the Company entered into an Asset Purchase Agreement and certain other ancillary agreements with Sebela International Limited, an Irish company resident in Bermuda (“ Sebela The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment and related costs to acquire the assets (excluding inventory) are included as part of product acquisition costs totaling $ 330,000 69,000

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”)
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the vesting period of the grant.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, notes payable, accounts payable, capital leases and other accrued liabilities at March 31, 2016 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, "Fair Value Measurements and Disclosures". ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company measures its derivative liability at fair value. The derivative embedded convertible option related to the Notes issued December 16, 2014 was valued using the “with” and “without” analysis. A “with” and “without” analysis is a standard valuation technique for valuing embedded derivatives by first considering the value of the Notes with the option and then considering the value of the Notes without the option. The difference is the fair value of the embedded derivatives. The embedded derivative is classified within Level 3 because it is valued using the “with” and “without” method, which does utilize inputs that are unobservable in the market. On May 20, 2015, the Company received approval to increase its authorized shares sufficient to allow for the conversion of the entire note into equity at its annual shareholders meeting. Therefore, the derivative liability of $ 18.3 23.1 108.8 143.75
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share Basic earnings (loss) per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the Notes and the exercise of options and warrants. For the three months ended March 31, 2016 and 2015 (in thousands except shares and per share data) 2016 2015 Basic earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Weighted average common shares - basic 53,031,351 52,841,900 Basic (loss) earnings per share $ (0.02) $ 0.12 Dillutive earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Interest expense related to convertible 3.75% senior notes - $ 1,348 Amortization of discount related to convertible 3.75% senior notes - $ 1,590 Change in the fair value of derivative - (8,625) Net (loss) income - diluted $ (950) $ 868 Share Computation: Weighted average common shares - basic 53,031,351 52,841,900 Effect of convertible 3.75% senior notes - 12,732,168 Effect of dilutive stock options and warrants - 1,636,109 Weighted average common shares outstanding - dilluted 53,031,351 67,210,177 Dilluted (loss) earnings per share $ (0.02) $ 0.01
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, “Revenue Recognition The Company derives its revenues from three basic types of transactions: sales of its own pharmaceutical products, sales of manufactured product for its customers included in product sales, and research and product development services and other services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Three months ended March 31, 2016 2015 Company product sales $ 9,191 $ 8,096 Contract manufacturing sales 6,231 2,414 Product sales, net $ 15,422 $ 10,510 Company Product Sales : The Company records revenue from Company product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales from Company label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of SRA is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the SRA reserves. The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90 95 Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses. (in thousands) Three months ended March 31, 2016 2015 Gross Company product sales $ 26,823 $ 22,307 Reduction to gross product sales: Chargebacks and billbacks 12,345 12,512 Sales discounts and other allowances 5,287 1,699 Total reduction to gross product sales 17,632 14,211 Company product sales, net $ 9,191 $ 8,096 Net Company product sales of $ 9.2 8.1 15.6 6.1 2.1 2.9 40 0.5 0.9 0.5 0.9 10,000 0 10,000 0 Contract Manufacturing Sales : The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products and are included in product sales, net on the Company’s Condensed Consolidated Statement of Operations. Research and Development Services and Other Income : The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed. Other types of revenue include royalty or licensing revenue, and would be recognized based upon the contractual agreement upon completion of the earnings process.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Major customers of the Company are defined as having revenue greater than 10 64 69 57 . Expansion into foreign operations in the fourth quarter of 2015 has generated net revenues greater than 10 13.4 2.2 136.4 52.1
Derivatives, Policy [Policy Text Block]	Derivatives The Company accounts for its derivative instruments in accordance with ASC 815-10, “Derivatives and Hedging”. ASC 815-10 establishes accounting and reporting standards requiring that derivative instruments, including derivative instruments embedded in other contracts, be recorded on the balance sheet as either an asset or liability measured at its fair value. ASC 815-10 also requires that changes in the fair value of derivative instruments be recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. The Company's derivative liability was the embedded convertible option of its Notes issued December 16, 2014 (see Note 6), which has been recorded as a liability at fair value until May 20, 2015, and was revalued at each reporting date, with changes in the fair value of the instruments included in the consolidated statements of operations as non-operating income (expense). Due to the approval of the sufficient shares at the Company’s annual shareholder meeting, the liability for the embedded derivative was reclassified to equity on May 20, 2015. The Company has no derivatives at March 31, 2016 and December 31, 2015.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In March 2016, the FASB ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): “Improvements to Employee Share-Based Payment Accounting”. The update includes multiple provisions intended to simplify various aspects of the accounting for share-based payments, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any interim or annual period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended March 31, 2016, the potential dilutive common stock equivalents have been excluded from the computation of diluted earnings (loss) per share, as their effect would have been anti-dilutive. For the three months ended March 31, 2016 and 2015 (in thousands except shares and per share data) 2016 2015 Basic earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Weighted average common shares - basic 53,031,351 52,841,900 Basic (loss) earnings per share $ (0.02) $ 0.12 Dillutive earnings (loss) per share computation: Net (loss) income - basic $ (950) $ 6,555 Interest expense related to convertible 3.75% senior notes - $ 1,348 Amortization of discount related to convertible 3.75% senior notes - $ 1,590 Change in the fair value of derivative - (8,625) Net (loss) income - diluted $ (950) $ 868 Share Computation: Weighted average common shares - basic 53,031,351 52,841,900 Effect of convertible 3.75% senior notes - 12,732,168 Effect of dilutive stock options and warrants - 1,636,109 Weighted average common shares outstanding - dilluted 53,031,351 67,210,177 Dilluted (loss) earnings per share $ (0.02) $ 0.01
Schedule of Product Information [Table Text Block]	Product Sales, net, include Company Product Sales and Contract Manufacturing Sales, as follows: Three months ended March 31, 2016 2015 Company product sales $ 9,191 $ 8,096 Contract manufacturing sales 6,231 2,414 Product sales, net $ 15,422 $ 10,510
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Gross-To-Net Sales Deductions (in thousands) Three months ended March 31, 2016 2015 Gross Company product sales $ 26,823 $ 22,307 Reduction to gross product sales: Chargebacks and billbacks 12,345 12,512 Sales discounts and other allowances 5,287 1,699 Total reduction to gross product sales 17,632 14,211 Company product sales, net $ 9,191 $ 8,096

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories at March 31, 2016 and December 31, 2015 consist of the following: March 31, 2016 December 31, 2015 (Unaudited) (Audited) ( in thousands) Raw materials $ 4,854 $ 4,833 Work in progress 98 128 Finished goods 5,139 4,024 Total $ 10,091 $ 8,985

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	March 31, 2016 December 31, 2015 (Unaudited) (Audited) (in thousands) Land $ 257 $ 257 Building and improvements 5,426 5,296 Machinery and equipment 6,967 5,270 Construction in progress 4,360 3,594 17,010 14,417 Less accumulated depreciation and amortization (5,885) (5,711) Property, plant and equipment, net $ 11,125 $ 8,706

Convertible 3.75% Senior Notes

Convertible 3.75% Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Debt [Table Text Block]	At March 31, 2016 and December 31, 2015, the net carrying amount of the Notes and the remaining unamortized debt discount were as follows: March 31, December 31, 2016 2015 (in thousands) Face amount of the Notes $ 143,750 $ 143,750 Unamortized discount 34,950 36,759 Carrying amount of the Notes $ 108,800 $ 106,991
Schedule of Long-term Debt Instruments [Table Text Block]	The assumptions used in connection with the valuation of the convertible option of the Notes issued December 16, 2014 utilizing the "with” and “without” method (discussed in Note 3) was as follows: Initial Measurement Measurement Measurement December 16, December 31, May 20, 2014 2014 2015 Issue date 12/17/2014 12/17/2014 12/17/2014 Maturity date 12/15/2019 12/15/2019 12/15/2019 Term 4.99 4.92 4.57 Principal (millions) 143.75 143.75 143.75 Coupon 3.75 % 3.75 % 3.75 % Seniority Senior unsecured Senior unsecured Senior unsecured Conversion shares 88.572 88.572 88.572 Conversion price $ 11.29 $ 11.29 $ 11.29 Stock price $ 9.45 $ 8.80 $ 5.73 Risk free rate 1.61 % 1.64 % 1.44 % Volatility (rounded) 40.00 % 40.00 % 46.00 %
Interest Income and Interest Expense Disclosure [Table Text Block]	For the three months ended March 31, 2016, and March 31, 2015, the Company recorded the following expenses in relation to the Notes: Three months ended March 31, 2016 March 31, 2015 (in thousands) Interest Expense at 3.75% coupon rate $ 1,347 $ 1,348 Debt discount amortization 1,809 1,590 Amortization of deferred financing costs 197 173 Total interest expense (1) $ 3,353 $ 3,111 (1) Included within "Interest and other expense, net" on the Consolidated Statements of Operations

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	Changes in goodwill during the quarter ended March 31, 2016 were as follows (in thousands): Goodwill December 31, 2015 $ 426 Acquisition - Impairments - Foreign currency translation 33 March 31, 2016 $ 459
Schedule of Finite and Indefinite Lived Intangible Assets [Table Text Block]	March 31, 2016 Weighted Average Gross Carrying Accumulated Net Carrying Remaining Amortization Amount Amortization Amount Period Trademarks and Technology $ 48,611 $ (1,269) $ 47,343 14.62 In process research and development ("IPR&D") 4,015 - 4,015 N/A - Indefinite lived Customer relationships 3,688 (131) 3,557 9.63 Total $ 56,315 $ (1,399) $ 54,916 December 31, 2015 Weighted Average Gross Carrying Accumulated Net Carrying Remaining Amortization Amount Amortization Amount Period Trademarks and Technology $ 47,679 $ (651) $ 47,028 14.8 In process research and development ("IPR&D") 3,875 - 3,875 N/A - Indefinite lived Customer relationships 3,460 (43) 3,417 9.9 Total $ 55,014 $ (694) $ 54,320
Schedule of Changes in Intangible Assets Other Than Goodwill [Table Text Block]	Changes in intangibles during the three months ended March 31, 2016 were as follows (in thousands): Trademarks and Customer Technology IPR&D Relationships December 31, 2015 $ 47,028 $ 3,875 3,417 Acquisition 330 - - Amortization (618) - (87) Foreign currency translation 603 140 227 March 31, 2016 47,343 4,015 3,557
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of March 31, 2016 over the remainder of 2016 and each of the next five years is estimated to be as follows ($ in thousands): Amortization Expense * 2016 (remainder of the year) $ 2,203 2017 2,937 2018 2,937 2019 2,937 2020 2,937 2021 2,937 *IPR&D amounts will be amortized once products become saleable, and are not included in the table above.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. The interest rates used are the U.S. Treasury yield curve in effect at the time of the grant. For the three months ended March 31, 2016 March 31, 2015 Expected volatility 68.0% - 69.9 % 52.7% - 55.2 % Expected term (in years) 3.2 -3.3 years 3.2 -3.3 years Risk-free rate 1.15 % 0.89% - 1.14 % Expected dividends 0 % 0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the 1999 Plan, the Director Plan and the 2009 Plan as of March 31, 2016 and changes during the period are presented below: Weighted Number of Average Options Exercise Price Outstanding as of January 1, 2016 3,592,734 $ 4.36 Issued 485,135 $ 7.46 Exercised (1,000) $ 1.10 Forfeited (31,000) $ 8.64 Expired - - Outstanding as of March 31, 2016 4,045,869 $ 4.70 Exercisable as of March 31, 2016 2,533,202 $ 2.57
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information regarding options outstanding and exercisable at March 31, 2016: Outstanding: Weighted Stock Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.79 - $1.00 50,000 $ 0.79 3.76 $1.01 - $1.50 1,861,400 $ 1.07 5.89 $1.51 - $10.67 2,134,469 $ 7.95 8.97 Total 4,045,869 $ 4.70 7.49 Exercisable: Stock Weighted Options Average Range of Exercise Prices Exercisable Exercise Price $0.79 - $1.00 50,000 $ 0.79 $1.01 - $1.50 1,851,400 $ 1.07 $1.51 - $10.67 631,802 $ 7.12 Total 2,533,202 $ 2.57
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Weighted Average RSUs Exercise Price Non-vested balance at January 1, 2016 182,750 $ 10.23 Changes during the period: Shares granted 58,068 7.50 Shares vested (52,584) 10.67 Shares forfeited - - Non-vested balance at March 31, 2016 188,234 $ 9.26

Stock Warrants (Tables)

Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Stock Warrant activity for the quarter ended March 31, 2015 consisted of: 2015 Weighted Number of Average Warrants Exercise Price Balance at January 1, 84,000 $ 1.21 Changes during the period: Stock warrants granted - - Stock warrants expired - - Stock warrants exercised - 1.21 Balance at March 31, 84,000 $ 1.21

Liquidity (Details Textual)

Liquidity (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
Liquidity Details [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 87,040	$ 157,031	$ 158,883	$ 87,191
Payments of Debt Issuance Costs	0	$ 9
Terminated Of Credit Facility	$ 10,000
Convertible Notes Payable [Member]
Liquidity Details [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.75%		3.75%	3.75%
Proceeds from Issuance of Senior Long-term Debt			$ 139,000
Payments of Debt Issuance Costs			$ 4,800

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basic earnings (loss) per share computation:
Net (loss) income - basic	$ (950)	$ 6,555
Weighted average common shares - basic	53,031,351	52,841,900
Basic (loss) earnings per share	$ (0.02)	$ 0.12
Dillutive earnings (loss) per share computation:
Net (loss) income - basic	$ (950)	$ 6,555
Interest expense related to convertible 3.75% senior notes	0	1,348
Amortization of discount related to convertible 3.75% senior notes	1,809	1,590
Change in the fair value of derivative	0	(8,625)
Net (loss) income - diluted	$ (950)	$ 868
Share Computation:
Weighted average common shares - basic	53,031,351	52,841,900
Effect of convertible 3.75% senior notes	0	12,732,168
Effect of dilutive stock options and warrants	0	1,636,109
Weighted average common shares outstanding - dilluted	53,031,351	67,210,177
Dilluted (loss) earnings per share	$ (0.02)	$ 0.01

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product sales, net	$ 15,422	$ 10,510
Company product sales
Product sales, net	9,191	8,096
Contract manufacturing sales
Product sales, net	$ 6,231	$ 2,414

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Reduction to gross product sales:
Company product sales, net	$ 15,422	$ 10,510
Gross Net Adjustments [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross Company product sales	26,823	22,307
Reduction to gross product sales:
Chargebacks and billbacks	12,345	12,512
Sales discounts and other allowances	5,287	1,699
Total reduction to gross product sales	17,632	14,211
Company product sales, net	$ 9,191	$ 8,096

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	May. 20, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Summary of Significant Accounting Policies Details [Line Items]
Accounts Payable and Accrued Liabilities		$ 2,100,000	$ 2,900,000
Unrealized Gain (Loss) on Derivatives		$ 0	$ 8,625,000
Percentage Of Net Sales For The Four Products For Royalty		40.00%	40.00%
Sales Revenue, Goods, Net, Total		$ 15,422,000	$ 10,510,000
Sales Revenue Goods Net Percent				10.00%
Assets		188,544,000		$ 184,762,000
Geographic Distribution, Domestic [Member]
Summary of Significant Accounting Policies Details [Line Items]
Sales Revenue, Goods, Net, Total		13,400,000
Assets		136,400,000
Geographic Distribution, Foreign [Member]
Summary of Significant Accounting Policies Details [Line Items]
Sales Revenue, Goods, Net, Total		2,200,000
Assets		52,100,000
Convertible Notes Payable [Member]
Summary of Significant Accounting Policies Details [Line Items]
Notes Payable, Fair Value Disclosure		108,800,000
Long-term Debt, Gross		$ 143,750,000
Unrealized Gain (Loss) on Derivatives				$ 23,100,000
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders Equity	$ 18,300,000
Customer Concentration Risk [Member]
Summary of Significant Accounting Policies Details [Line Items]
Concentration Risk, Percentage		64.00%	69.00%
Percentage of Accounts Receivable		57.00%
Percent Of Revenue		10.00%
Royalty [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accounts Payable and Accrued Liabilities		$ 500,000	$ 900,000
Royalty Expense		$ 500,000	900,000
Maximum [Member]
Summary of Significant Accounting Policies Details [Line Items]
Wholesaler Percent of Chargeback Payments		95.00%
Minimum [Member]
Summary of Significant Accounting Policies Details [Line Items]
Wholesaler Percent of Chargeback Payments		90.00%
Net Of SRA Balance [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accounts Receivable, Net		$ 15,600,000	6,100,000
IGI Product [Member]
Summary of Significant Accounting Policies Details [Line Items]
Sales Revenue, Goods, Net, Total		9,200,000	8,100,000
IGI Product [Member] | Royalty [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accounts Payable and Accrued Liabilities		10,000	0
Royalty Expense		$ 10,000	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 4,854	$ 4,833
Work in progress	98	128
Finished goods	5,139	4,024
Total	$ 10,091	$ 8,985

Property, Plant and Equipment35

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	$ 17,010	$ 14,417
Less accumulated depreciation and amortization	(5,885)	(5,711)
Property, plant and equipment, net	11,125	8,706
Land [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	257	257
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	5,426	5,296
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	6,967	5,270
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	$ 4,360	$ 3,594

Property, Plant and Equipment36

Property, Plant and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 174,000	$ 118,000
Interest Costs Capitalized	$ 22,000	$ 0

Convertible 3.75% Senior Note37

Convertible 3.75% Senior Notes (Details) - Convertible Notes Payable [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Face amount of the Notes	$ 143,750	$ 143,750
Unamortized discount	34,950	36,759
Carrying amount of the Notes	$ 108,800	$ 106,991

Convertible 3.75% Senior Note38

Convertible 3.75% Senior Notes (Details 1) - Convertible Debt [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	May. 20, 2015	Dec. 31, 2014	Dec. 16, 2014
Debt Instrument [Line Items]
Issue date	Dec. 17, 2014	Dec. 17, 2014	Dec. 17, 2014
Maturity date	Dec. 15, 2019	Dec. 15, 2019	Dec. 15, 2019
Term	4 years 6 months 25 days	4 years 11 months 1 day	4 years 11 months 26 days
Principal (millions)	$ 143,750	$ 143,750	$ 143,750
Coupon	3.75%	3.75%	3.75%
Seniority	Senior unsecured	Senior unsecured	Senior unsecured
Conversion shares	88.572	88.572	88.572
Conversion price	$ 11.29	$ 11.29	$ 11.29
Stock price	$ 5.73	$ 8.8	$ 9.45
Risk free rate	1.44%	1.64%	1.61%
Volatily (rounded)	46.00%	40.00%	40.00%

Convertible 3.75% Senior Note39

Convertible 3.75% Senior Notes (Details 2) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Interest Expense at 3.75% coupon rate		$ 0	$ 1,348
Debt discount amortization		1,809	1,590
Amortization of deferred financing costs		197	195
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Interest Expense at 3.75% coupon rate		1,347	1,348
Debt discount amortization		1,809	1,590
Amortization of deferred financing costs		197	173
Total interest expense	[1]	$ 3,353	$ 3,111
[1]	Included within "Interest and other expense, net" on the Consolidated Statements of Operations

Convertible 3.75% Senior Note40

Convertible 3.75% Senior Notes (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	May. 20, 2015	Dec. 22, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 16, 2014
Debt Instrument [Line Items]
Payments of Debt Issuance Costs			$ 0	$ 9
Deferred Tax Liabilities, Deferred Expense, Deferred Financing Costs			3,800	4,600
Unrealized Gain (Loss) on Derivatives			0	8,625
Qualified Institutional Buyers [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 18,750					$ 125,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 143,750					$ 143,750	143,750
Proceeds from Issuance of Senior Long-term Debt		139,000
Payments of Debt Issuance Costs		$ 4,800
Interest Payable			$ 1,600
Debt Instrument, Convertible, Terms of Conversion Feature			The Notes are convertible at an initial conversion price of approximately $11.29 per share, which is equivalent to an initial conversion rate of 88.5716 shares per $1,000 principal amount of Notes, subject to adjustment in certain events, such as distributions of dividends or stock splits. Holders may convert their Notes at their option prior to September 15, 2019, when or if certain conditions have been met or circumstances have occurred, such as if the Company’s stock price exceeds 130% of the conversion price under the Notes for a designated period of time, or if the trading price of the Notes is, for a designated period of time, less than 98% of the closing sale price of the Company’s common stock multiplied by the then-current conversion rate of the Notes, or if  the Company calls Notes for redemption, or if certain specified corporate events occur. Holders may also convert their Notes at their option at any time on or after September 15, 2019 and prior to the close of business on the business day immediately preceding the stated maturity date. In addition, following the occurrence of certain changes of control of the Company described in the Indenture governing the Notes or termination of trading of the Company’s common stock or other securities into which the Notes are convertible (a “make-whole fundamental change”) or the delivery by the Company of a notice of redemption, the conversion rate for a holder who elects to convert its Notes in connection with such make-whole fundamental change or such notice of redemption will increase in certain circumstances. Additionally, subject to certain conditions, the Company may redeem for cash any or all outstanding Notes on or after December 19, 2017 in an amount equal to the outstanding principal amount of such Notes, plus accrued and unpaid interest.
Derivative Liability				$ 8,600			$ 43,700
Debt Instrument, Interest Rate, Effective Percentage							12.94%
Debt Instrument, Interest Rate, Stated Percentage	3.75%					3.75%	3.75%
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity	$ 18,300
Unrealized Gain (Loss) on Derivatives					$ 23,100
Debt Instrument, Convertible, Remaining Discount Amortization Period			3 years 9 months

Goodwill and Intangible Asset41

Goodwill and Intangible Assets (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill Beginning balance	$ 426
Acquisition	0
Impairments	0
Foreign currency translation	33
Goodwill Ending balance	$ 459

Goodwill and Intangible Asset42

Goodwill and Intangible Assets (Details 1) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Gross Carrying Amount	$ 56,315	$ 55,014
Accumulated Amortization	(1,399)	(694)
Net Carrying Amount	54,916	54,320
In process research and development ("IPR&D) [Member]
Gross Carrying Amount	4,015	3,875
Accumulated Amortization	0	0
Net Carrying Amount	4,015	3,875
Customer Relationships [Member]
Gross Carrying Amount	3,688	3,460
Accumulated Amortization	(131)	(43)
Net Carrying Amount	$ 3,557	$ 3,417
Weighted Average Remaining Amortization Period	9 years 7 months 17 days	9 years 10 months 24 days
Trademarks and Technology [Member]
Gross Carrying Amount	$ 48,611	$ 47,679
Accumulated Amortization	(1,269)	(651)
Net Carrying Amount	$ 47,343	$ 47,028
Weighted Average Remaining Amortization Period	14 years 7 months 13 days	14 years 9 months 18 days

Goodwill and Intangible Asset43

Goodwill and Intangible Assets (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Finite Lived Intangible Assets Net, Beginning balance	$ 54,320
Amortization	(705)	$ (30)
Finite Lived Intangible Assets Net, Ending balance	54,916
IPR&D [Member]
Finite Lived Intangible Assets Net, Beginning balance	3,875
Acquisition	0
Amortization	0
Foreign currency translation	140
Finite Lived Intangible Assets Net, Ending balance	4,015
Customer Relationships [Member]
Finite Lived Intangible Assets Net, Beginning balance	3,417
Acquisition	0
Amortization	(87)
Foreign currency translation	227
Finite Lived Intangible Assets Net, Ending balance	3,557
Trademarks and Technology [Member]
Finite Lived Intangible Assets Net, Beginning balance	47,028
Acquisition	330
Amortization	(618)
Foreign currency translation	603
Finite Lived Intangible Assets Net, Ending balance	$ 47,343

Goodwill and Intangible Asset44

Goodwill and Intangible Assets (Details 3) $ in Thousands	Mar. 31, 2016USD ($)	[1]
2016 (remainder of the year)	$ 2,203
2,017	2,937
2,018	2,937
2,019	2,937
2,020	2,937
2,021	$ 2,937
[1]	IPR&D amounts will be amortized once products become saleable, and are not included in the table above.

Goodwill and Intangible Asset45

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Goodwill	$ 459	$ 426

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Based Compensation [Line Items]
Risk-free rate	1.15%
Expected dividends	0.00%	0.00%
Minimum [Member]
Stock Based Compensation [Line Items]
Expected volatility	68.00%	52.70%
Expected term (in years)	3 years 2 months 12 days	3 years 2 months 12 days
Risk-free rate		0.89%
Maximum [Member]
Stock Based Compensation [Line Items]
Expected volatility	69.90%	55.20%
Expected term (in years)	3 years 3 months 18 days	3 years 3 months 18 days
Risk-free rate		1.14%

Stock-Based Compensation (Det47

Stock-Based Compensation (Details 1) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Stock Based Compensation [Line Items]
Number of Options Outstanding, Balance Beginning | shares	3,592,734
Number of Options Issued | shares	485,135
Number of Options Exercised | shares	(1,000)
Number of Options Forfeited | shares	(31,000)
Number of Options Expired | shares	0
Number of Options Outstanding, Balance Ending | shares	4,045,869
Number of Options Exercisable | shares	2,533,202
Weighted Average Exercise Price Outstanding, Balance Beginning | $ / shares	$ 4.36
Weighted Average Exercise Price Issued | $ / shares	7.46
Weighted Average Exercise Price Exercised | $ / shares	1.10
Weighted Average Exercise Price Forfeited | $ / shares	8.64
Weighted Average Exercise Price Expired | $ / shares	0
Weighted Average Exercise Price Outstanding, Balance Ending | $ / shares	4.70
Weighted Average Exercise Price Exercisable | $ / shares	$ 2.57

Stock-Based Compensation (Det48

Stock-Based Compensation (Details 2)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options | shares	4,045,869
Options Outstanding, Weighted Average Exercise Price	$ 4.70
Options Outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 26 days
Options Exercisable, Number of Options | shares	2,533,202
Options Exercisable, Weighted Average Exercise Price	$ 2.57
Exercise Price Range, One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	0.79
Options Outstanding, Exercise Price Range, Upper Range Limit	$ 1
Options Outstanding, Number of Options | shares	50,000
Options Outstanding, Weighted Average Exercise Price	$ 0.79
Options Outstanding, Weighted Average Remaining Contractual Term	3 years 9 months 4 days
Options Exercisable, Number of Options | shares	50,000
Options Exercisable, Weighted Average Exercise Price	$ 0.79
Exercise Price Range, Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	1.01
Options Outstanding, Exercise Price Range, Upper Range Limit	$ 1.50
Options Outstanding, Number of Options | shares	1,861,400
Options Outstanding, Weighted Average Exercise Price	$ 1.07
Options Outstanding, Weighted Average Remaining Contractual Term	5 years 10 months 20 days
Options Exercisable, Number of Options | shares	1,851,400
Options Exercisable, Weighted Average Exercise Price	$ 1.07
Exercise Price Range, Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	1.51
Options Outstanding, Exercise Price Range, Upper Range Limit	$ 10.67
Options Outstanding, Number of Options | shares	2,134,469
Options Outstanding, Weighted Average Exercise Price	$ 7.95
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 11 months 19 days
Options Exercisable, Number of Options | shares	631,802
Options Exercisable, Weighted Average Exercise Price	$ 7.12

Stock-Based Compensation (Det49

Stock-Based Compensation (Details 3) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Stock Based Compensation [Line Items]
Number Of Restricted Stock And RSUs, Non-Vested | shares	182,750
Weighted Average Exercise Price, Non-vested Balance Beginning | $ / shares	$ 10.23
Changes during the period:
Shares granted | shares	58,068
Shares granted - Weighted Average Exercise Price | $ / shares	$ 7.50
Shares vested | shares	(52,584)
Shares vested - Weighted Average Exercise Price | $ / shares	$ 10.67
Shares forfeited | shares	0
Shares forfeited - Weighted Average Exercise Price | $ / shares	$ 0
"Number of Restricted Stock and RSUs, Non-vested | shares	188,234
Weighted Average Exercise Price, Non-vested Balance Ending | $ / shares	$ 9.26

Stock-Based Compensation (Det50

Stock-Based Compensation (Details Textual) - USD ($)	Apr. 12, 2010	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	May. 29, 2010
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 3.53	$ 3.84
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 4,800,000
Common Stock, Shares, Outstanding		53,059,273		53,000,689
Director Stock Option Plan - 1999 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,975,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,634,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		807,782
Common Stock, Shares, Outstanding		650,000
Nineteen Ninety Nine Stock Incentive Plan [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		3,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,892,500
Percent FMV Common Stock Options Granted		100.00%
Plan 2009 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,506,248
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		230,420
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		3,395,869
Restricted Stock [Member]
Stock Based Compensation Details [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 1,600,000
Allocated Share-based Compensation Expense		$ 180,000	$ 99,300
Restricted Stock [Member] | Plan 2009 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		188,234
Director Plan And The 2009 Plan [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		4,045,869
Common Stock, Capital Shares Reserved for Future Issuance		122,201
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 7,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		7,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 3,800

Stock Warrants (Details)

Stock Warrants (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2015$ / sharesshares
Beginning balance (in shares) | shares	84,000
Beginning balance (in dollars per share) | $ / shares	$ 1.21
Changes during the period:
Stock warrants granted (in shares) | shares	0
Stock warrants granted (in dollars per share) | $ / shares	$ 0
Stock warrants expired (in shares) | shares	0
Stock warrants expired (in dollars per share) | $ / shares	$ 0
Stock warrants exercised (in shares) | shares	0
Stock warrants exercised (in dollars per share) | $ / shares	$ 1.21
Ending balance (in shares) | shares	84,000
Ending balance (in dollars per share) | $ / shares	$ 1.21

Stock Warrants (Details Textual

Stock Warrants (Details Textual)	Dec. 08, 2010$ / sharesshares
Stock Warrants [Line Items]
Class of Warrant or Right Expiration Date	Dec. 8, 2015
First Placement Agent [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	338,182
Second Placement Agent [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,364
Warrant Issuedin Connection with Private Placement Offering [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares	$ 1.21

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2010
Income Tax Examination [Line Items]
Change in Ownership Percent	50.00%
Stockholder Ownership	5.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	20.00%
Operating Loss Carryforwards		$ 35.6
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	0.00%
Effective Income Tax Rate Reconciliation, Deduction, Dividend, Percent	20.00%
Not Subject to Limitations [Member] | Subsequent To Change Date In 2010 [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards			$ 7.8
Subject to Limitations [Member] | Minimum [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards			1
Subject to Limitations [Member] | Maximum [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards			$ 2.3

Legal (Details Textual)

Legal (Details Textual)	3 Months Ended
	Mar. 31, 2016
Legal and U.S. Regulatory Proceedings Details [Line Items]
Loss Contingency, Settlement Agreement, Terms	On December 4, 2015, Galderma Laboratories, L.P. and Galderma S.A., collectively referred to as Galderma, filed a complaint in the United States District Court for the Northern District of Texas against the Company alleging infringement of United States Patent No. 6,106,848 based upon the Companys submission to the FDA of an ANDA seeking FDA approval to market clobetasol propionate lotion 0.05% before the expiration patent asserted in the complaint.

Asset Purchase Agreements (Deta

Asset Purchase Agreements (Details Textual) - Sebela International Limited [Member]	3 Months Ended
	Mar. 31, 2016USD ($)
Payments to Acquire Productive Assets	$ 69,000
Business Combination, Acquisition Related Costs	$ 330,000